Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCB2Z0)

• Drug Name: BEY2153 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMCB2Z0

Molecule-Related Drug Atlas

Drug(s) Targeting Microtubule-associated protein tau (MAPT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LMT-X	DMOFIBM	Acute myeloid leukaemia	2A60	Phase 3	[3]
Davunetide	DMD7K9X	Cognitive impairment	6D71	Phase 3	[4]
TRx0237	DM0QNF4	Alzheimer disease	8A20	Phase 3	[5]
E2814	DMZ3Q59	Alzheimer disease	8A20	Phase 2/3	[6]
PBT-2	DMKWGS1	Alzheimer disease	8A20	Phase 2	[7]
RG6100	DMEFD0B	Alzheimer disease	8A20	Phase 2	[8]
Tau-binding PET tracer	DM9QFW2	Alzheimer disease	8A20	Phase 2	[4]
BIIB092	DM263RP	Progressive supranuclear palsy	8A00.10	Phase 2	[8]
Semorinemab	DMA17VD	Alzheimer disease	8A20	Phase 2	[9]
Bepranemab	DMRQIJO	Alzheimer disease	8A20	Phase 2	[10]

Drug(s) Targeting Amyloid beta A4 protein (APP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nirogacestat	DMUP5Z0	Desmoid tumour	2F7C	Approved	[11]
Aducanumab	DM51JW4	Alzheimer disease	8A20	Approved	[12]
Lecanemab	DMW03YD	Alzheimer disease	8A20	Approved	[13]
Florbetapir F-18	DMJ8A3Z	Diagnostic imaging	N.A.	Approved	[14]
GV-971	DMTMA5W	Alzheimer disease	8A20	Approved in China	[15]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[16]
Solanezumab	DM0HIU5	Alzheimer disease	8A20	Phase 3	[17]
Tramiprosate	DM7BSRH	Alzheimer disease	8A20	Phase 3	[18]
Bapineuzumab	DMHQ5GK	Alzheimer disease	8A20	Phase 3	[19]
ALZT-OP1	DMG5BTD	Alzheimer disease	8A20	Phase 3	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Amyloid beta A4 protein (APP)	TTE4KHA	A4_HUMAN	Inhibitor	[2]
Microtubule-associated protein tau (MAPT)	TTS87KH	TAU_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04476303) A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of BEY2153 After Oral Administration in Healthy Young and Elderly Male Volunteers. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of BeyondBio
• [3] Clinical pipeline report, company report or official report of TauRx.
• [4] Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
• [5] Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296.
• [6] Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. Acta Neuropathol Commun. 2020 Feb 4;8(1):13.
• [7] PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Sci Transl Med. 2021 May 12;13(593):eabb2639.
• [10] Immunotherapy for Alzheimer's disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18.
• [13] The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [15] Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019 Oct;29(10):787-803.
• [16] Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9.
• [17] Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21.
• [18] Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47.
• [19] Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82.
• [20] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)